Development and validation of the Oral Lichen Planus-Disease Activity Scale: a novel tool for comprehensive clinical assessment
Issued Date
2024-09-01
Resource Type
ISSN
14326981
eISSN
14363771
Scopus ID
2-s2.0-85201224659
Pubmed ID
39129032
Journal Title
Clinical Oral Investigations
Volume
28
Issue
9
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Oral Investigations Vol.28 No.9 (2024)
Suggested Citation
Somsak P., Piboonratanakit P., Pongsiriwet S., Sappayatosok K., Sarideechaigul W., Taebunpakul P., Pimolbutr K., Ayudhya C.C.N., Pengpis N., Wiriyakijja P. Development and validation of the Oral Lichen Planus-Disease Activity Scale: a novel tool for comprehensive clinical assessment. Clinical Oral Investigations Vol.28 No.9 (2024). doi:10.1007/s00784-024-05875-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/100573
Title
Development and validation of the Oral Lichen Planus-Disease Activity Scale: a novel tool for comprehensive clinical assessment
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: To develop and validate the Oral Lichen Planus-Disease Activity Scale (OLP-DAS) for assessing overall disease activity of OLP. Methods: The OLP-DAS was created by refining the Thongprasom criteria, incorporating inputs from the literature and expert review, and integrating pain assessment. Content validity was evaluated in a virtual meeting with 8 Oral Medicine specialists. Reliability and validity of the final version were examined. Seventeen OLP subjects were assessed for disease activity by 10 investigators using the OLP-DAS, Oral Disease Severity Score (ODSS), OLP-Investigator Global Assessment (OLP-IGA), and Reticular-Erythema-Ulcerative (REU) scale. Convergent validity was assessed by rating 160 OLP subjects using the OLP-DAS, ODSS, and OLP-IGA. Inter-rater and intra-rater reliability, along with convergent validity, were analyzed using intraclass correlation coefficients (ICCs) and Spearman’s rank correlation coefficients (rs). Results: The final OLP-DAS achieved excellent content validity indices. Inter-rater and intra-rater ICCs for total OLP-DAS scores were 0.93 and 0.96, respectively. Total OLP-DAS scores exhibited strong positive correlations with the ODSS and OLP-IGA (rs = 0.94 and rs = 0.76; P < 0.001, respectively). The OLP Severity Index (OLP-SI), a component of the OLP-DAS, showed very strong positive correlations with OLP disease activity parameters of the ODSS (rs = 0.90; P < 0.001). Conclusions: The OLP-DAS is a valid and reliable clinician-reported outcome measure (CROM) for evaluating OLP disease activity. Clinical relevance: The OLP-DAS, as a standardized CROM for OLP, is valuable for both routine clinical assessments and research applications.